Skip to main content
Premium Trial:

Request an Annual Quote

RXi Begins Second Phase IIa Trial of Anti-scarring Drug


NEW YORK (GenomeWeb) – RXi Pharmaceuticals this week announced the start of a Phase IIa trial of its siRNA-based anti-scarring drug RXI-109 for the prevention of keloid recurrence.

RXI-109 comprises siRNAs designed to inhibit connective tissue growth factor, or CTGF, a protein linked to wound healing and other fibrotic processes. It employs the company's proprietary self-delivering technology, which enables cellular uptake without the need for a delivery vehicle.

In the placebo-controlled Phase IIa study, patients with two keloids — a type of scar composed primarily of collagen — of similar size and location are selected for keloidectomy. After the procedure, the lesions will be closed, and one will be treated with RXI-109. Patients will be followed for six months to evaluate the clinical evolution of the lesions.

This latest study follows the initiation of an ongoing Phase IIa trial of RXI-109 in patients with pre-existing hypertrophic scars. These patients undergo scar-revision surgery, after which one end of the scar is treated and the other end receives placebo.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.